Allarity Therapeutics (ALLR) Stock Statistics & Valuation Metrics

Allarity Therapeutics has a market cap or net worth of $21.80M. The enterprise value is $9.09.

Allarity Therapeutics has 15,910,724 shares outstanding. The number of shares has decreased by -2.65% in one year.

Allarity Therapeutics’s return on equity (ROE) is -1.14 and return on invested capital (ROIC) is -112.26%.

The current PE Ratio of Allarity Therapeutics is ―. Allarity Therapeutics’s PEG ratio is 0.01.

In the last 12 months, Allarity Therapeutics had revenue of 320.00K and earned -11.23M in profits. Earnings per share was -0.78.

In the last 12 months, operating cash flow was -13.71M and capital expenditures -64.00K, giving a free cash flow of -13.78M billion.

Allarity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Allarity Therapeutics upcoming earnings date is Oct 13, 2026, After Close (Confirmed).

Allarity Therapeutics as a current ratio of 2.13, with Debt / Equity ratio of 630.26%

In the past 12 months, Allarity Therapeutics has paid 0.00 in taxes.

Allarity Therapeutics EV to EBITDA ratio is -0.20, with an EV/FCF ratio of -0.15.

Allarity Therapeutics has $16.98M in cash and marketable securities with $22.29M in debt, giving a net cash position of -$5.30M billion.

Gross margin is 107.54%, with operating margin of -3939.06%, and net profit margin of -3509.69%.

The average price target for Allarity Therapeutics is $10.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy